Robert Liptak - Net Worth and Insider Trading

Robert Liptak Net Worth

The estimated net worth of Robert Liptak is at least $2 Million dollars as of 2024-09-20. Robert Liptak is the Director of Globus Medical Inc and owns about 26,159 shares of Globus Medical Inc (GMED) stock worth over $2 Million. Details can be seen in Robert Liptak's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Robert Liptak has not made any transactions after 2016-01-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Robert Liptak

Robert Liptak Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Robert Liptak owns 12 companies in total, including Globus Medical Inc (GMED) , Entasis Therapeutics Holdings Inc (ETTX) , and Forty Seven Inc (FTSV) among others .

Click here to see the complete history of Robert Liptak’s form 4 insider trades.

Insider Ownership Summary of Robert Liptak

Ticker	Comapny	Transaction Date	Type of Owner
GMED	Globus Medical Inc	2016-01-06	director & 10 percent owner
ETTX	Entasis Therapeutics Holdings Inc	2018-09-25	10 percent owner
FTSV	Forty Seven Inc	2018-07-02	10 percent owner
		2017-10-11	10 percent owner
		2016-02-08	10 percent owner
		2015-06-15	10 percent owner
		2013-09-25	10 percent owner
		2013-10-25	10 percent owner
		2014-10-28	10 percent owner
		2012-06-04	10 percent owner
		2011-09-16	10 percent owner
		2003-06-26	10 percent owner

Robert Liptak Latest Holdings Summary

Robert Liptak currently owns a total of 1 stock. Robert Liptak owns 26,159 shares of Globus Medical Inc (GMED) as of January 6, 2016, with a value of $2 Million.

Latest Holdings of Robert Liptak

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
GMED	Globus Medical Inc	2016-01-06	26,159	70.60	1,846,825

Holding Weightings of Robert Liptak

Robert Liptak Form 4 Trading Tracker

According to the SEC Form 4 filings, Robert Liptak has made a total of 0 transactions in Globus Medical Inc (GMED) over the past 5 years. The most-recent trade in Globus Medical Inc is the sale of 15,300 shares on January 6, 2016, which brought Robert Liptak around $420,750.

Insider Trading History of Robert Liptak

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Robert Liptak Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Robert Liptak Ownership Network

Ownership Network List of Robert Liptak

No Data

Ownership Network Relation of Robert Liptak

Robert Liptak Owned Company Details

What does Globus Medical Inc do?

Who are the key executives at Globus Medical Inc?

Robert Liptak is the director & 10 percent owner of Globus Medical Inc. Other key executives at Globus Medical Inc include director & Vice President & Operations David D Davidar , SVP & General Counsel Kelly Huller , and SVP & Chief Financial Officer Keith W Pfeil .

Globus Medical Inc (GMED) Insider Trades Summary

Over the past 18 months, Robert Liptak made no insider transaction in Globus Medical Inc (GMED). Other recent insider transactions involving Globus Medical Inc (GMED) include a net sale of 106,750 shares made by Dan Lemaitre , a net sale of 45,000 shares made by David D Davidar , and a net sale of 11,590 shares made by Leslie V Norwalk .

In summary, during the past 3 months, insiders sold 41,000 shares of Globus Medical Inc (GMED) in total and bought 0 shares, with a net sale of 41,000 shares. During the past 18 months, 185,840 shares of Globus Medical Inc (GMED) were sold and 0 shares were bought by its insiders, resulting in a net sale of 185,840 shares.

Globus Medical Inc (GMED)'s detailed insider trading history can be found in Insider Trading Tracker table.

Globus Medical Inc Insider Transactions

No Available Data

What does Entasis Therapeutics Holdings Inc do?

Who are the key executives at Entasis Therapeutics Holdings Inc?

Robert Liptak is the 10 percent owner of Entasis Therapeutics Holdings Inc. Other key executives at Entasis Therapeutics Holdings Inc include 10 percent owner Theravance Inc , VP & Principal Fin & Acct Off Kristie Ann Wagner , and General Counsel Elizabeth M Keiley .

Entasis Therapeutics Holdings Inc (ETTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Entasis Therapeutics Holdings Inc (ETTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Entasis Therapeutics Holdings Inc (ETTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Entasis Therapeutics Holdings Inc (ETTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Entasis Therapeutics Holdings Inc Insider Transactions

No Available Data

What does Forty Seven Inc do?

Who are the key executives at Forty Seven Inc?

Robert Liptak is the 10 percent owner of Forty Seven Inc. Other key executives at Forty Seven Inc include Chief Financial Officer Ann D Rhoads , 10 percent owner Lightspeed General Partner X, L.p. , and 10 percent owner Lightspeed Ultimate General Partner X, Ltd. .

Forty Seven Inc (FTSV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Forty Seven Inc (FTSV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Forty Seven Inc (FTSV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Forty Seven Inc (FTSV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Forty Seven Inc Insider Transactions

No Available Data

What does Venus Concept Inc do?

Who are the key executives at Venus Concept Inc?

Robert Liptak is the 10 percent owner of Venus Concept Inc. Other key executives at Venus Concept Inc include 10 percent owner Michael Willingham Masters , President Global Sales Ross Portaro , and 10 percent owner Masters Special Situations, Llc .

Venus Concept Inc (VERO) Insider Trades Summary

Over the past 18 months, Robert Liptak made no insider transaction in Venus Concept Inc (VERO). Other recent insider transactions involving Venus Concept Inc (VERO) include a net sale of 489,948 shares made by Michael Willingham Masters ,

In summary, during the past 3 months, insiders sold 0 shares of Venus Concept Inc (VERO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 489,948 shares of Venus Concept Inc (VERO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 489,948 shares.

Venus Concept Inc (VERO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Venus Concept Inc Insider Transactions

No Available Data

What does TetraLogic Pharmaceuticals Corp do?

Who are the key executives at TetraLogic Pharmaceuticals Corp?

Robert Liptak is the 10 percent owner of TetraLogic Pharmaceuticals Corp. Other key executives at TetraLogic Pharmaceuticals Corp include other: See Remarks Hudson Bay Capital Management Lp , other: See Remarks Lazard Asset Management Llc , and other: See Remarks Nomura Holdings Inc .

TetraLogic Pharmaceuticals Corp (TLOG) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of TetraLogic Pharmaceuticals Corp (TLOG) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of TetraLogic Pharmaceuticals Corp (TLOG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

TetraLogic Pharmaceuticals Corp (TLOG)'s detailed insider trading history can be found in Insider Trading Tracker table.

TetraLogic Pharmaceuticals Corp Insider Transactions

No Available Data

What does Oxford Immunotec Global PLC do?

Who are the key executives at Oxford Immunotec Global PLC?

Robert Liptak is the 10 percent owner of Oxford Immunotec Global PLC. Other key executives at Oxford Immunotec Global PLC include director & Chief Executive Officer Peter Wrighton-smith , Chief Financial Officer Mclaughlin Matthew T E , and Chief Operating Officer Stefan C Linn .

Oxford Immunotec Global PLC (OXFD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Oxford Immunotec Global PLC (OXFD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Oxford Immunotec Global PLC (OXFD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Oxford Immunotec Global PLC (OXFD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Oxford Immunotec Global PLC Insider Transactions

No Available Data

What does IVERIC bio Inc do?

Who are the key executives at IVERIC bio Inc?

Robert Liptak is the 10 percent owner of IVERIC bio Inc. Other key executives at IVERIC bio Inc include SVP & COO Keith Westby , SVP & CFO and Treasurer David Francis Carroll , and Senior Vice President & CCO Christopher Paul Simms .

IVERIC bio Inc (ISEE) Insider Trades Summary

Over the past 18 months, Robert Liptak made no insider transaction in IVERIC bio Inc (ISEE). Other recent insider transactions involving IVERIC bio Inc (ISEE) include a net sale of 140,000 shares made by Keith Westby , and a net sale of 113,500 shares made by David Francis Carroll .

In summary, during the past 3 months, insiders sold 0 shares of IVERIC bio Inc (ISEE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 253,500 shares of IVERIC bio Inc (ISEE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 253,500 shares.

IVERIC bio Inc (ISEE)'s detailed insider trading history can be found in Insider Trading Tracker table.

IVERIC bio Inc Insider Transactions

No Available Data

What does Aerie Pharmaceuticals Inc do?

Who are the key executives at Aerie Pharmaceuticals Inc?

Robert Liptak is the 10 percent owner of Aerie Pharmaceuticals Inc. Other key executives at Aerie Pharmaceuticals Inc include Chief Financial Officer Peter Frederick Lang , director & Chief Executive Officer Raj Kannan , and Vice President of Finance Jeffrey Calabrese .

Aerie Pharmaceuticals Inc (AERI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aerie Pharmaceuticals Inc (AERI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aerie Pharmaceuticals Inc (AERI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aerie Pharmaceuticals Inc (AERI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aerie Pharmaceuticals Inc Insider Transactions

No Available Data

What does Sientra Inc do?

Who are the key executives at Sientra Inc?

Robert Liptak is the 10 percent owner of Sientra Inc. Other key executives at Sientra Inc include director & President and CEO Ronald Menezes , General Counsel and VP Oliver Christian Bennett , and Chief Financial Officer Andrew C Schmidt .

Sientra Inc (SIENQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sientra Inc (SIENQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sientra Inc (SIENQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sientra Inc (SIENQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sientra Inc Insider Transactions

No Available Data

What does Achillion Pharmaceuticals Inc do?

Who are the key executives at Achillion Pharmaceuticals Inc?

Robert Liptak is the 10 percent owner of Achillion Pharmaceuticals Inc. Other key executives at Achillion Pharmaceuticals Inc include EVP & Chief Commercial Officer Paul E Firuta , EVP & Chief Medical Officer Steven Zelenkofske , and General Counsel Martha E Manning .

Achillion Pharmaceuticals Inc (ACHN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Achillion Pharmaceuticals Inc (ACHN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Achillion Pharmaceuticals Inc (ACHN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Achillion Pharmaceuticals Inc (ACHN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Achillion Pharmaceuticals Inc Insider Transactions

No Available Data

What does Zogenix Inc do?

Who are the key executives at Zogenix Inc?

Robert Liptak is the 10 percent owner of Zogenix Inc. Other key executives at Zogenix Inc include EVP & CHIEF COMMERCIAL OFFICER Ashish M Sagrolikar , EVP/Chief Development Officer Gail M Farfel , and director & President and CEO Stephen J Farr .

Zogenix Inc (ZGNX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Zogenix Inc (ZGNX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Zogenix Inc (ZGNX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Zogenix Inc (ZGNX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Zogenix Inc Insider Transactions

No Available Data

What does Rigel Pharmaceuticals Inc do?

Who are the key executives at Rigel Pharmaceuticals Inc?

Robert Liptak is the 10 percent owner of Rigel Pharmaceuticals Inc. Other key executives at Rigel Pharmaceuticals Inc include EVP & Chief Financial Officer Dean L Schorno , Sr VP of Bus Dev and Com Ops Raul R Rodriguez , and EVP & Chief Commercial Officer David A Santos .

Rigel Pharmaceuticals Inc (RIGL) Insider Trades Summary

Over the past 18 months, Robert Liptak made no insider transaction in Rigel Pharmaceuticals Inc (RIGL). Other recent insider transactions involving Rigel Pharmaceuticals Inc (RIGL) include a net sale of 52,894 shares made by Raul R Rodriguez , a net sale of 14,519 shares made by David A Santos , and a net sale of 12,628 shares made by Dean L Schorno .

In summary, during the past 3 months, insiders sold 0 shares of Rigel Pharmaceuticals Inc (RIGL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 8,004 shares of Rigel Pharmaceuticals Inc (RIGL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 8,004 shares.

Rigel Pharmaceuticals Inc (RIGL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rigel Pharmaceuticals Inc Insider Transactions

No Available Data

Robert Liptak Mailing Address

Above is the net worth, insider trading, and ownership report for Robert Liptak. You might contact Robert Liptak via mailing address: The John Hancock Tower, 200 Clarendon Street, 54th Floor, Boston Ma 02116.

Discussions on Robert Liptak

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.